Prospective study to compare rhGH and LAGH metabolic outcomes in GHD children, stratified by IGF-1 levels
Background
Children with growth hormone deficiency (GHD) require treatment with growth hormone, typically recombinant human growth hormone (rhGH). The emergence of long-acting growth hormone (LAGH) offers less frequent dosing, but comparative long-term metabolic and auxological outcomes are not fully understood. Crucially, both abnormally low and high insulin-like growth factor-I (IGF-1) levels are linked to increased metabolic and cardiovascular risks. This study aims to characterize these outcomes, especially considering the influence of IGF-1 levels, to optimize GHD management.
Study Design
The METAB-BELGROW-LAGH study is a prospective, observational study enrolling Belgian children diagnosed with GHD. Participants will receive either daily rhGH or weekly LAGH as part of their standard-of-care treatment over a three-year period. Data collection occurs at baseline, 6, 12, 24, and 36 months, encompassing clinical, auxological, and biological parameters. The study will also assess additional metabolic markers, inflammatory, and endothelial biomarkers. A subset of patients will undergo carotid intima-media thickness (cIMT) measurements and DEXA-scan for body fat distribution.
Why It Matters
This prospective study is critical for understanding the long-term impact of different growth hormone regimens on the metabolic and growth profiles of children with GHD. By comparing daily rhGH and weekly LAGH and stratifying by IGF-1 levels, the research could identify optimal treatment strategies. The findings may lead to personalized GHD management protocols, potentially mitigating metabolic and cardiovascular risks associated with specific IGF-1 profiles. This will inform clinical guidelines, helping clinicians select the most appropriate GH therapy to improve patient outcomes and quality of life.
growth hormone deficiency
ghd
rhgh
lagh
igf-1
pediatric